Pfenex Inc. is planning to undertake an offering of its common stock.
The San Diego-based biotechnology company expects to grant the underwriters an option to buy additional shares.
Pfenex intends to use the net proceeds to fund expenses in connection with obtaining regulatory approval, commercialization and launch of its osteoporosis medicine PF708, to conduct ongoing research and development, and for general corporate purposes and working capital.
Barclays Capital Inc. and William Blair & Co. LLC are acting as joint book-running managers for the offering.
